Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

Pancreatic

Pancreatic cancer.

Must-know

  1. 1

    KRAS ctDNA after resection of pancreatic cancer

    Groot et al. Clinical Cancer Research. 2019.

    Detection of ctDNA during follow-up after pancreatectomy was associated with a median overall survival of 17 months. Median overall survival was not reached at 30 months for patients without ctDNA.

    PMID 31142500DOI

  2. 2

    ctDNA after resection of localized pancreatic cancer

    Sausen et al. Nature Communications. 2015.

    ctDNA after resection predicted clinical relapse and was detected a median of 6.5 months before CT.

    PMID 26154128DOI

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

Presentations

Accruing studies for Pancreatic

Trials

GIPancreaticTier 3PinnedMRD / ctDNABiomarkers

Postoperative Tumor-Informed Circulating Tumor DNA Status for Molecular Residual Disease Detection After Curative-Intent Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis

A systematic review and meta-analysis of five observational cohorts (237 patients) found that postoperative tumor-informed ctDNA positivity after curative-intent PDAC resection was associated with higher radiological recurrence (RR 2.50, 95% CI 1.90-3.28) and shorter disease-free and overall survival (HRs 8.11 and 5.15); the authors caution that a negative result did not reliably exclude residual disease.

Journal of Gastrointestinal Cancer